Show simple item record

dc.contributor.authorAspuria, Paul-Joseph P.
dc.contributor.authorLunt, Sophia Yunkyungkwon
dc.contributor.authorVäremo, Leif
dc.contributor.authorVergnes, Laurent
dc.contributor.authorGozo, Maricel
dc.contributor.authorBeach, Jessica A
dc.contributor.authorSalumbides, Brenda
dc.contributor.authorReue, Karen
dc.contributor.authorWiedemeyer, W. R.
dc.contributor.authorNielsen, Jens Kromann
dc.contributor.authorKarlan, Beth Y.
dc.contributor.authorOrsulic, Sandra
dc.date.accessioned2014-12-24T16:24:27Z
dc.date.available2014-12-24T16:24:27Z
dc.date.issued2014-12
dc.date.submitted2014-05
dc.identifier.issn2049-3002
dc.identifier.urihttp://hdl.handle.net/1721.1/92499
dc.description.abstractSuccinate dehydrogenase (SDH) is a mitochondrial metabolic enzyme complex involved in both the electron transport chain and the citric acid cycle. SDH mutations resulting in enzymatic dysfunction have been found to be a predisposing factor in various hereditary cancers. Therefore, SDH has been implicated as a tumor suppressor. We identified that dysregulation of SDH components also occurs in serous ovarian cancer, particularly the SDH subunit SDHB. Targeted knockdown of Sdhb in mouse ovarian cancer cells resulted in enhanced proliferation and an epithelial-to-mesenchymal transition (EMT). Bioinformatics analysis revealed that decreased SDHB expression leads to a transcriptional upregulation of genes involved in metabolic networks affecting histone methylation. We confirmed that Sdhb knockdown leads to a hypermethylated epigenome that is sufficient to promote EMT. Metabolically, the loss of Sdhb resulted in reprogrammed carbon source utilization and mitochondrial dysfunction. This altered metabolic state of Sdhb knockdown cells rendered them hypersensitive to energy stress. These data illustrate how SDH dysfunction alters the epigenetic and metabolic landscape in ovarian cancer. By analyzing the involvement of this enzyme in transcriptional and metabolic networks, we find a metabolic Achilles' heel that can be exploited therapeutically. Analyses of this type provide an understanding how specific perturbations in cancer metabolism may lead to novel anticancer strategies.en_US
dc.description.sponsorshipFoundation for Women’s Cancer (Lynette Medlin-Brumfield/Mary-Jane Welker Ovarian Cancer Early Detection Research Grant)en_US
dc.description.sponsorshipAlex's Lemonade Stand Foundationen_US
dc.description.sponsorshipMargaret E. Early Medical Research Trusten_US
dc.description.sponsorshipSandy Rollman Foundationen_US
dc.description.sponsorshipUnited States. Dept. of Defense (Ovarian Cancer Clinical Translational Leverage Award (W81XWH-13-OCRP-TLA))en_US
dc.description.sponsorshipAmerican Cancer Society (RSG-10-252-01-TBG)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (grant P01 HL28481)en_US
dc.description.sponsorshipNational Center for Research Resources (U.S.) (NCRR S10RR026744)en_US
dc.description.sponsorshipOvarian Cancer Research Fund (Liz Tilberis Scholarship)en_US
dc.description.sponsorshipUnited States. Defense Advanced Research Projects Agency (CDMRP Visionary Postdoctoral Award number W81XWH-12-1-0466)en_US
dc.publisherBioMed Central Ltd.en_US
dc.relation.isversionofhttp://dx.doi.org/10.1186/2049-3002-2-21en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0en_US
dc.sourceBioMed Central Ltden_US
dc.titleSuccinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolismen_US
dc.typeArticleen_US
dc.identifier.citationAspuria, Paul-Joseph P., Sophia Y. Lunt, Leif Varemo, Laurent Vergnes et al. "Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism." Cancer & Metabolism. (2014 Dec 15); 2 (1):21.en_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.audience.educationlevel
dc.contributor.mitauthorLunt, Sophia Yunkyungkwonen_US
dc.relation.journalCancer & Metabolismen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2014-12-15T08:18:35Z
dc.language.rfc3066en
dc.rights.holderPaul-Joseph P Aspuria et al.; licensee BioMed Central Ltd.
dspace.orderedauthorsAspuria, Paul-Joseph P; Lunt, Sophia Y; Väremo, Leif; Vergnes, Laurent; Gozo, Maricel; Beach, Jessica A; Salumbides, Brenda; Reue, Karen; Wiedemeyer, W; Nielsen, Jens; Karlan, Beth Y; Orsulic, Sandraen_US
dspace.mitauthor.errortrue
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record